Texas A&M University

tamu.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

122

Active

28

Phase 3

1

Total enrollment

18,341

Pipeline matrix

Showing 1 of 1 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ketamine1

Next readouts

  • 2026-12-31

Top conditions

  • Chronic Obstructive Pulmonary Disease8
  • Obesity7
  • Healthy5
  • Protein Metabolism5
  • Periodontitis4
  • Cardiovascular Diseases4
  • Cancer3
  • Snoring3

Frequently asked questions about Texas A&M University

How many clinical trials does Texas A&M University have on ClinicalTrials.gov?
Texas A&M University is listed as the lead sponsor on 122 clinical trials in ClinicalTrials.gov, 28 of which are currently active (recruiting, enrolling, or ongoing).
How many of Texas A&M University's trials are in Phase 3?
1 of Texas A&M University's trials are in Phase 3, spread across 1 active drug program.
What therapeutic areas does Texas A&M University focus on?
Texas A&M University's most-studied conditions on ClinicalTrials.gov are Chronic Obstructive Pulmonary Disease, Obesity, Healthy, Protein Metabolism, Periodontitis.
When are Texas A&M University's next clinical trial readouts?
Texas A&M University has 1 upcoming primary-completion readout tracked here; the soonest is “Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression”, expected around 2026-12-31.